Galapagos collaborates with BridGene Biosciences for small molecule drugs

Galapagos announced a strategic collaboration and licensing agreement with BridGene Biosciences, a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets. Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC, to discover novel small molecule drug candidates against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize. The preclinical research collaboration will focus on oncology targets named by Galapagos. Galapagos will pay BridGene up to $27M in upfront and preclinical research milestone payments and more than $700M in clinical and commercial milestones, assuming success of the programs. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration.